BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30055872)

  • 21. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation.
    Xiong Y; Taleb M; Misawa K; Hou Z; Banerjee S; Amador-Molina A; Jones DR; Chintala NK; Adusumilli PS
    Nat Cancer; 2023 Jul; 4(7):1001-1015. PubMed ID: 37336986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.
    Hombach AA; Geumann U; Günther C; Hermann FG; Abken H
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21.
    Ptáčková P; Musil J; Štach M; Lesný P; Němečková Š; Král V; Fábry M; Otáhal P
    Cytotherapy; 2018 Apr; 20(4):507-520. PubMed ID: 29475789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor-T Cells with 4-1BB Co-Stimulatory Domain Present a Superior Treatment Outcome than Those with CD28 Domain Based on Bioinformatics.
    Zhong Q; Zhu YM; Zheng LL; Shen HJ; Ou RM; Liu Z; She YL; Chen R; Li C; Huang J; Yao MD; Zhang Q; Liu S
    Acta Haematol; 2018; 140(3):131-140. PubMed ID: 30253384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
    Cherkassky L; Morello A; Villena-Vargas J; Feng Y; Dimitrov DS; Jones DR; Sadelain M; Adusumilli PS
    J Clin Invest; 2016 Aug; 126(8):3130-44. PubMed ID: 27454297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals.
    Fujiwara K; Kitaura M; Tsunei A; Kusabuka H; Ogaki E; Okada N
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33804441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
    Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
    Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.
    Li S; Zhang J; Wang M; Fu G; Li Y; Pei L; Xiong Z; Qin D; Zhang R; Tian X; Wei Z; Chen R; Chen X; Wan J; Chen J; Wei X; Xu Y; Zhang P; Wang P; Peng X; Yang S; Shen J; Yang Z; Chen J; Qian C
    Br J Haematol; 2018 May; 181(3):360-371. PubMed ID: 29637550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TGF-β suppresses RasGRP1 expression and supports regulatory T cell resistance against p53-induced CD28-dependent T-cell apoptosis.
    Takami M; Cunha C; Motohashi S; Nakayama T; Iwashima M
    Eur J Immunol; 2018 Dec; 48(12):1938-1943. PubMed ID: 30298904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation.
    McKarns SC; Schwartz RH; Kaminski NE
    J Immunol; 2004 Apr; 172(7):4275-84. PubMed ID: 15034041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galunisertib enhances chimeric antigen receptor-modified T cell function.
    Wang Z; Liu Q; Risu N; Fu J; Zou Y; Tang J; Li L; Liu H; Zhou G; Zhu X
    Eur J Histochem; 2020 Jun; 64(s2):. PubMed ID: 32705856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
    Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
    J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response.
    Tiemessen MM; Kunzmann S; Schmidt-Weber CB; Garssen J; Bruijnzeel-Koomen CA; Knol EF; van Hoffen E
    Int Immunol; 2003 Dec; 15(12):1495-504. PubMed ID: 14645158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication.
    Kloss CC; Lee J; Zhang A; Chen F; Melenhorst JJ; Lacey SF; Maus MV; Fraietta JA; Zhao Y; June CH
    Mol Ther; 2018 Jul; 26(7):1855-1866. PubMed ID: 29807781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells.
    Chen W; Jin W; Wahl SM
    J Exp Med; 1998 Nov; 188(10):1849-57. PubMed ID: 9815262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
    Finney HM; Akbar AN; Lawson AD
    J Immunol; 2004 Jan; 172(1):104-13. PubMed ID: 14688315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
    Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
    Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.
    Tang N; Cheng C; Zhang X; Qiao M; Li N; Mu W; Wei XF; Han W; Wang H
    JCI Insight; 2020 Feb; 5(4):. PubMed ID: 31999649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors.
    Hartley J; Abken H
    Clin Transl Immunology; 2019; 8(6):e1064. PubMed ID: 31236274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.